Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Employees - 214,
CEO - Dr. Keith Michael Gottesdiener M.D., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 154.27M
Altman ZScore(max is 10): -4.16, Piotroski Score(max is 10): 3, Working Capital: $129477000, Total Assets: $328163000, Retained Earnings: $-739102000, EBIT: -206518000, Total Liabilities: $221239000, Revenue: $41620000
AryaFin Target Price - $1.19 - Current Price $1.17 - Analyst Target Price $9.40
| Ticker | PRME |
| Index | RUT |
| Curent Price | 1.17 |
| Change | -11.99% |
| Market Cap | 154.27M |
| Average Volume | 1.65M |
| Income | -202.01M |
| Sales | 3.85M |
| Book Value/Share | 0.82 |
| Cash/Share | 1.10 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | Sep 10, 2019 |
| Employees | 214 |
| Moving Avg 20days | -21.01% |
| Moving Avg 50days | -26.06% |
| Moving Avg 200days | -60.55% |
| Shares Outstanding | 131.16M |
| Earnings Date | May 08 BMO |
| Inst. Ownership | 28.62% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 40.07 |
| Price/Book | 1.44 |
| Price/Cash | 1.07 |
| Price/FCF | - |
| Quick Ratio | 4.78 |
| Current Ratio | 4.78 |
| Debt/Equity | 1.13 |
| Return on Assets | -63.17% |
| Return on Equity | -115.21% |
| Return on Investment | -91.32% |
| Gross Margin | -69.34% |
| Ops Margin | -5369.68% |
| Profit Margin | -5252.50% |
| RSI | 40.11 |
| BETA(β) | 1.57 |
| From 52week Low | 5.38% |
| From 52week High | -85.79% |
| EPS | -1.66 |
| EPS next Year | -1.04 |
| EPS next Qtr | -0.35 |
| EPS this Year | 23.09% |
| EPS next 5 Year | 16.68% |
| EPS past 5 Year | -124.13% |
| Sales past 5 Year | -20.00% |
| EPS Y/Y | 22.37% |
| Sales Y/Y | 550.76% |
| EPS Q/Q | 9.47% |
| Sales Q/Q | 146.02% |
| Sales Surprise | -67.60% |
| EPS Surprise | -27.59% |
| ATR(14) | 0.20 |
| Perf Week | -7.48% |
| Perf Month | -15.47% |
| Perf Quarter | -64.23% |
| Perf Year | -83.31% |
| Perf YTD | -59.76% |
| Target Price | 9.40 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer